Sunshine Biopharma Company Insiders
| SBFMW Stock | USD 0.24 0.04 20.00% |
Sunshine Biopharma employs about 44 people. The company is managed by 7 executives with a total tenure of roughly 103 years, averaging almost 14.0 years of service per executive, having 6.29 employees per reported executive. Recap of Sunshine Biopharma's management performance can provide insight into the venture performance.
Sunshine |
Sunshine Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1798) %, meaning that it generated substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.16 in 2025. Return On Capital Employed is likely to climb to -0.19 in 2025. At this time, Sunshine Biopharma's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 30.1 M in 2025, despite the fact that Non Currrent Assets Other are likely to grow to (1.7 M).Common Stock Shares Outstanding is likely to climb to about 26.5 K in 2025, despite the fact that Net Loss is likely to grow to (10.6 M).
Sunshine Biopharma Workforce Comparison
Sunshine Biopharma Warrant is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,098. Sunshine Biopharma holds roughly 44.0 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.13. Sunshine Biopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sunshine Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Camille Sebaaly over three months ago Acquisition by Camille Sebaaly of 30000 shares of Sunshine Biopharma at 0.7635 subject to Rule 16b-3 | ||
Steve Slilaty over six months ago Acquisition by Steve Slilaty of 1100000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Steve Slilaty over six months ago Acquisition by Steve Slilaty of 321305416 shares of Sunshine Biopharma at 0.0026 subject to Rule 16b-3 |
Sunshine Biopharma Notable Stakeholders
A Sunshine Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sunshine Biopharma often face trade-offs trying to please all of them. Sunshine Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sunshine Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steve Slilaty | President Chairman | Profile | |
| Robert Ferreira | President Inc | Profile | |
| Camille Sebaaly | CFO Secretary | Profile | |
| Abderrazzak Merzouki | Chief Director | Profile | |
| Malek Chamoun | Chief Officer | Profile | |
| Michel Roy | Chief Officer | Profile | |
| Marc Beaudoin | Chief Officer | Profile |
About Sunshine Biopharma Management Performance
The success or failure of an entity such as Sunshine Biopharma often depends on how effective the management is. Sunshine Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sunshine management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sunshine management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.16) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.24) | (0.23) |
Please note, the imprecision that can be found in Sunshine Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sunshine Biopharma Warrant. Check Sunshine Biopharma's Beneish M Score to see the likelihood of Sunshine Biopharma's management manipulating its earnings.
Sunshine Biopharma Workforce Analysis
Traditionally, organizations such as Sunshine Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sunshine Biopharma within its industry.Sunshine Biopharma Manpower Efficiency
Return on Sunshine Biopharma Manpower
| Revenue Per Employee | 547.6K | |
| Revenue Per Executive | 3.4M | |
| Net Loss Per Employee | 102.4K | |
| Net Loss Per Executive | 643.7K | |
| Working Capital Per Employee | 439.5K | |
| Working Capital Per Executive | 2.8M |
Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.